Clinical Trials Directory

Trials / Completed

CompletedNCT04089501

The Role of the Pregnane X Receptor (PXR) in Indole Signaling and Intestinal Permeability in Inflammatory Bowel Disease

Status
Completed
Phase
Study type
Observational
Enrollment
43 (actual)
Sponsor
Albert Einstein College of Medicine · Academic / Other
Sex
All
Age
65 Years
Healthy volunteers
Not accepted

Summary

The goal of this study is to better understand the mechanisms responsible for the development of and the severity of Inflammatory Bowel Disease (IBD), such as Crohn's Disease and Ulcerative Colitis, which cause inflammation of the gut as well as potentially affecting other areas of the body

Detailed description

Based on promising preliminary data, the study will characterize the claim that PXR signaling serves as a key mechanistic link between the host environment and the innate immune system in the gut. It is widely believed that one cause of IBD stems from abnormal sensing of commensal bacteria. The research will shed light on the molecular mechanisms used by gut barrier epithelial cells in sensing commensals and regulating inflammatory responses in the gut. This will provide a new mechanism towards which more mechanisms derived probiotics could be used to abrogate intestinal inflammation. It is hoped that these agents would eventually serve as non-toxic alternatives or adjuncts to currently available therapeutics for IBD. The research protocol will involve the collection of feces, either by self-collection or through colonoscopic washing.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTStool collectionStool will be collected from subjects who have been diagnosed with IBD or whom small intestinal, colonic or ileocolonic and have signed consent for the control group. Stool will be self-collected or through routine colonoscopy procedure.
DIAGNOSTIC_TESTBiopsy collection3 additional biopsies (for research purposes) will be taken from patients who undergo colonoscopy as per standard of care

Timeline

Start date
2015-02-25
Primary completion
2019-05-02
Completion
2019-05-02
First posted
2019-09-13
Last updated
2019-09-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04089501. Inclusion in this directory is not an endorsement.